Gene and cell therapy using cell fusion technology
AssigneeSeoul National University Hospital
InventorsJung-Joon SUNG, Seung-Yong SEONG, Hee-Woo LEE, Ki Yoon Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.
Claims13
A method for reducing cell damage, comprising:
- administering a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins to a subject with a therapeutically effective dose.
A method for treating neurodegenerative diseases or neurological diseases, comprising:
- administering a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins or a cell transformed with the vector to a subject with a therapeutically effective dose.
A method for treating degenerative muscular diseases or muscular diseases, comprising:
- administering a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins or a cell transformed with the vector to a subject with a therapeutically effective dose.
Dependencies are inferred from the claim text.